New drug candidate BI 3731579 enters human testing
NCT ID NCT06429137
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called BI 3731579 in healthy male volunteers to see if it is safe and how the body handles it. Participants receive a single oral dose of the drug or a placebo, with different groups getting higher doses. The study measures side effects and drug levels in the blood to understand the drug's behavior.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 3731579
- What this could lead to
- If successful, this early trial could pave the way for further studies of BI 3731579 as a potential treatment for future conditions.
- What could go wrong
- This is a very early, small trial focused on safety and drug processing, not effectiveness. The drug may not prove safe or may not work as hoped in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test